SilicoPharm
Polypharmacological in silico screening platform for the next generation drugs

Publication


Abstract


The GABAB receptor (GABAB-R) is a heterodimeric class C G protein-coupled receptor comprised of the GABAB1a/b and GABAB2 subunits. The endogenous orthosteric agonist γ-amino-butyric acid (GABA) binds within the extracellular Venus flytrap (VFT) domain of the GABAB1a/b subunit. The receptor is associated with numerous neurological and neuropsychiatric disorders including learning and memory deficits, depression and anxiety, addiction and epilepsy, and is an interesting target for new drug development. Ligand- and structure-based virtual screening (VS) are used to identify hits in preclinical drug discovery. In the present study, we have evaluated classical ligand-based in silico methods, fingerprinting and pharmacophore mapping and structure-based in silico methods, structure-based pharmacophores, docking and scoring, and linear interaction approximation (LIA) for their aptitude to identify orthosteric GABAB-R compounds. Our results show that the limited number of active compounds and their high structural similarity complicate the use of ligand-based methods. However, by combining ligand-based methods with different structure-based methods active compounds were identified in front of DUDE-E decoys and the number of false positives was reduced, indicating that novel orthosteric GABAB-R compounds may be identified by a combination of ligand-based and structure-based in silico methods.

Reference


@article{Evenseth2019,
  author = "L. M. Evenseth and D. Warszycki and A. J. Bojarski and M. Gabrielsen and I. Sylte",
  title = "In silico methods for the discovery of orthosteric GABAB receptor compounds",
  year = 2019,
  journal = "Molecules",
  volume = 24,
  keywords = "gabab receptor, ligand-based screening, orthosteric binding site, structure-based screening, virtual screening",
  doi = "10.3390/molecules24050935"
}